Does One Voriconazole Breakpoint Suit All Candida Species?

Does one voriconazole breakpoint suit all Candida species?

Non-species-dependent interpretative breakpoints for voriconazole and Candida species were proposed by the Antifungal Susceptibility Subcommittee of the Clinical and Laboratory Standards Institute in January 2005 (susceptible, 1 g/ml; susceptible dose dependent [SDD], 1 to 2 g/ml; and resistant, 4 g/ml) (11). The proposed breakpoints were based on the MIC distribution profile, pharmacokinetic a...

Accelerometer wear-site detection: When one site does not suit all, all of the time.

OBJECTIVES Choice of accelerometer wear-site may facilitate greater compliance in research studies. We aimed to test whether a simple method could automatically discriminate whether an accelerometer was worn on the hip or wrist from free-living data. DESIGN Cross-sectional. METHODS Twenty-two 10-12y old children wore a GENEActiv at the wrist and at the hip for 7-days. The angle between the ...

In vitro activity of voriconazole against Candida species.

The in vitro activity of voriconazole was compared with that of itraconazole and fluconazole against 181 isolates of Candida albicans, 124 isolates of Candida glabrata, and 20 isolates of Candida krusei obtained from the early 1980s through the mid-1990s. Voriconazole had greater intrinsic activity than fluconazole or itraconazole against all three Candida species. For C. glabrata, C. krusei, a...

Oral voriconazole dose in children: one size does not fit all.

To the Editor—We read with interest the article by Neely et al [1], who reported their clinical pharmacokinetic and phar-macodynamic experience with voricona-zole in pediatric patients. The article raises interesting issues about the pharmacologic rationale for the approved oral dose of voriconazole in children. According to European recommendations , a fixed 200-mg oral dose should be given tw...

Does one size fit all?